Literature DB >> 26201001

Peripheral arterial disease in heterozygous familial hypercholesterolemia.

Carolina Pereira1, Marcio H Miname2, Marcia R P Makdisse3, Carolina Watanabe4, Antonio E Pesaro3, Cinthia E Jannes4, Roberto Kalil Filho2, Alexandre C Pereira4, Raul D Santos5.   

Abstract

BACKGROUND: Familial hypercholesterolemia is characterized by elevated plasma cholesterol and early coronary arterial disease onset. However, few studies investigated the association of heterozygous familial hypercholesterolemia with peripheral arterial disease.
METHODS: In a cross sectional study 202 heterozygous familial hypercholesterolemia patients (91% confirmed by molecular diagnosis) were compared to 524 normolipidemic controls. Peripheral arterial disease was diagnosed by ankle-brachial index values ≤0.90.
RESULTS: Compared with controls, familial hypercholesterolemia patients were older, more often female, with higher rates of hypertension, diabetes, previous coronary disease and higher total cholesterol levels. Smoking (previous and former) was more common among controls. The prevalence of peripheral arterial disease was 17.3 and 2.3% respectively in familial hypercholesterolemia and controls (p < 0.001). Results persisted after matching familial hypercholesterolemia and controls by a propensity score. Regression analyses demonstrated that age (odds ratio- OR = 1.03 95% CI 1.00-1.05, p = 0.033), previous cardiovascular disease (OR = 3.12 CI 95% 1.56-6.25, p = 0.001) and familial hypercholesterolemia diagnosis (OR = 5.55 CI 95% 2.69-11.44, p< 0.001) were independently associated with peripheral arterial disease. Among familial hypercholesterolemia patients, age (OR 1.05, 95% CI 1.02-1.09, p = 0.005), intermittent claudication (OR 6.32, 95% CI 2.60-15.33, p< 0.001) and smoking (OR 2.44, 95% CI 1.08-5.52, p = 0.032) were associated with peripheral arterial disease.
CONCLUSIONS: Peripheral arterial disease is more frequent in familial hypercholesterolemia than in normolipidemic subjects and it should routine screened in these individuals even if asymptomatic. However, its role as predictor of cardiovascular events needs to be ascertained prospectively.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Familial hypercholesterolemia; Peripheral artery disease

Mesh:

Substances:

Year:  2015        PMID: 26201001     DOI: 10.1016/j.atherosclerosis.2015.07.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.

Authors:  Dalton Bertolim Précoma; Gláucia Maria Moraes de Oliveira; Antonio Felipe Simão; Oscar Pereira Dutra; Otávio Rizzi Coelho; Maria Cristina de Oliveira Izar; Rui Manuel Dos Santos Póvoa; Isabela de Carlos Back Giuliano; Aristóteles Comte de Alencar Filho; Carlos Alberto Machado; Carlos Scherr; Francisco Antonio Helfenstein Fonseca; Raul Dias Dos Santos Filho; Tales de Carvalho; Álvaro Avezum; Roberto Esporcatte; Bruno Ramos Nascimento; David de Pádua Brasil; Gabriel Porto Soares; Paolo Blanco Villela; Roberto Muniz Ferreira; Wolney de Andrade Martins; Andrei C Sposito; Bruno Halpern; José Francisco Kerr Saraiva; Luiz Sergio Fernandes Carvalho; Marcos Antônio Tambascia; Otávio Rizzi Coelho-Filho; Adriana Bertolami; Harry Correa Filho; Hermes Toros Xavier; José Rocha Faria-Neto; Marcelo Chiara Bertolami; Viviane Zorzanelli Rocha Giraldez; Andrea Araújo Brandão; Audes Diógenes de Magalhães Feitosa; Celso Amodeo; Dilma do Socorro Moraes de Souza; Eduardo Costa Duarte Barbosa; Marcus Vinícius Bolívar Malachias; Weimar Kunz Sebba Barroso de Souza; Fernando Augusto Alves da Costa; Ivan Romero Rivera; Lucia Campos Pellanda; Maria Alayde Mendonça da Silva; Aloyzio Cechella Achutti; André Ribeiro Langowiski; Carla Janice Baister Lantieri; Jaqueline Ribeiro Scholz; Silvia Maria Cury Ismael; José Carlos Aidar Ayoub; Luiz César Nazário Scala; Mario Fritsch Neves; Paulo Cesar Brandão Veiga Jardim; Sandra Cristina Pereira Costa Fuchs; Thiago de Souza Veiga Jardim; Emilio Hideyuki Moriguchi; Jamil Cherem Schneider; Marcelo Heitor Vieira Assad; Sergio Emanuel Kaiser; Ana Maria Lottenberg; Carlos Daniel Magnoni; Marcio Hiroshi Miname; Roberta Soares Lara; Artur Haddad Herdy; Cláudio Gil Soares de Araújo; Mauricio Milani; Miguel Morita Fernandes da Silva; Ricardo Stein; Fernando Antonio Lucchese; Fernando Nobre; Hermilo Borba Griz; Lucélia Batista Neves Cunha Magalhães; Mario Henrique Elesbão de Borba; Mauro Ricardo Nunes Pontes; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2019-11-04       Impact factor: 2.000

2.  Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.

Authors:  Aaron W Aday; Patrick R Lawler; Nancy R Cook; Paul M Ridker; Samia Mora; Aruna D Pradhan
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

Review 3.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

4.  Association of smoking with coronary artery disease in Nepalese populations: a case control study.

Authors:  Til Bahadur Basnet; Cheng Xu; Manthar Ali Mallah; Wiwik Indayati; Cheng Shi; Jin Xu; Aihua Gu
Journal:  Toxicol Res (Camb)       Date:  2019-06-28       Impact factor: 3.524

5.  Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC).

Authors:  Hugh Tunstall-Pedoe; Sanne A E Peters; Mark Woodward; Allan D Struthers; Jill J F Belch
Journal:  J Am Heart Assoc       Date:  2017-09-18       Impact factor: 5.501

6.  Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania.

Authors:  Cristiana-Elena Vlad; Liliana Foia; Laura Florea; Irina-Iuliana Costache; Andreea Covic; Roxana Popescu; Delia Reurean-Pintilei; Adrian Covic
Journal:  Lipids Health Dis       Date:  2021-01-11       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.